Advertisement

Archives of Gynecology and Obstetrics

, Volume 254, Issue 1–4, pp 130–135 | Cite as

Wirkungsweisen und klinischer Einsatz von Antigestagenen

  • Joseph Neulen
Reproduktionsmedizin Gynäkologische Endokrinologie Und Fortpflanzungsmedizin
  • 21 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Van Look, P.F.A., Bygdeman, M., 1989 Antiprogestational steroids: a new dimendion in human fertility. Reviews of reproductive Biology(S.Milligan), pp 2–44, Oxford Univ. PressGoogle Scholar
  2. 2.
    Benhamou, B. et al. 1989 A single amino acid that determinates the sensivity of progesteron receptors to RU 486 Science 245, 206–209,Google Scholar
  3. 3.
    Baulieu, E.E. 1989 Contragestion and other clinical applications of RU 486, antiprogesterone at the receptor Science 245, 1351–1357PubMedGoogle Scholar
  4. 4.
    Klein-Hitpass, L. et al. 1991 Two types of antiprogestines identified by their differential action in transcriptionally active extracsts from T47D cells Nuclein Acid Research 19, 1227–1234Google Scholar
  5. 5.
    Wolf, J.P. et al. 1989 Contraceptive potential of RU 486 by ovulation inhibition: II; II. Suppresion of pituitary gonadotropin secretion in vitro Contraception 40, 185–193CrossRefPubMedGoogle Scholar
  6. 6.
    Ortmann, O. et al. 1989 Inhibitoty effects of the antiprogestin, RU 486, on progesterone actions and luteinizing hormone secretion in pituitary gonadotrophs J. Steroid Biochem. 32, 291–297CrossRefPubMedGoogle Scholar
  7. 7.
    Uilenbroek, J.T. 1991 Hormone concentrations and ovualtory response in rats treated with antiprogestagenes j.Endocrinol. 129, 423–429PubMedGoogle Scholar
  8. 8.
    Koering, M.J. et al., 1986 Morphologic response of endometrium to a progesterone receptor antagonist, RU 486, in monkey Ferti.Stirel 45, 280–287Google Scholar
  9. 9.
    Shoupe, D. et al., 1987 Effect of the antiprogesterone Ru 486 in normal women. I. single dose administration in the midluteal phase Am. j. Obstet. Gynecol. 157, 1415–1420PubMedGoogle Scholar
  10. 10.
    Shoupe, D. et al. 1987 Effect of the antiprogesterone Ru 486 in normal women; II. Administration in the late luteal phase Am. J. Obstet. Gynecol. 157, 1421–1426PubMedGoogle Scholar
  11. 11.
    Ledger, W.L. et al. 1992 Inhibition of ovulation by low dose mifeprestone (RU 486) Hum Reprod. 7, 945–950PubMedGoogle Scholar
  12. 12.
    Batista, M.C. et al. 1992 Evidence for a critical role of progesterone in the regulation of the mydcycle gonadotropin surge ans ovulation JCEM 74, 565–570PubMedGoogle Scholar
  13. 13.
    Schmidt, P.J. et al. 1991 Lack of effect of induced menses on symptomes in women with premenstrual syndrome N. Engl. J. Med. 324, 1174–1179PubMedGoogle Scholar
  14. 14.
    Baulieu, E.E. 1989 Contragestion with RU 486: a new approach to postovulatory fertility control Acta Obstet. Gynecol. Scand. Suppl. 149, 5–8PubMedGoogle Scholar
  15. 15.
    Swahn, M.L. et al. 1991 Contraception with mifepristone Lancet 338, 942–943CrossRefPubMedGoogle Scholar
  16. 16.
    WHO 1991 Pregnancy termination with mifepristone and gemeprost: a multicentre comparison between repeated doses and a single dose of mifepristone Fertil. Steril 56, 32–40Google Scholar
  17. 17.
    Delay, M. et al. 1992 Arret cardiocirculatoire apres administration de l'association mifepristone (MifgyneR) sulprostone (NaladorR) pour interruption de grossesse. Role evoque du spasma coronaire Arch. Mal. Coeur. Vaiss. 85, 105–107PubMedGoogle Scholar
  18. 18.
    Norman, J.E. et al. 1991 Uterine contractility and induction of abortion in early pregnancy by mosoprristol and mifepristone Lancet 338, 122–1236CrossRefGoogle Scholar
  19. 19.
    Cingotti, M. et al. 1990 Traitement de la grossesse extra uterine par le RU 486. A propos d'un cas. Rev. Fr. Gynecol. Obstet. 85, 611–613Google Scholar
  20. 20.
    Kelly, R.W. et al. 1992 Choriodecidual produktion of interleukin-8 and mechanism of parturition Lancet 339, 776–777PubMedGoogle Scholar
  21. 21.
    Urquhart, D.R., Templeton, A.A. 1990 The use of mifepristone prior to prostaglandine induced midtrimester abortion Hum. Reprod. 5, 883–886PubMedGoogle Scholar
  22. 22.
    Chwalisz, K. et al. 1991 The progesteerone antagonist onapristone increases the effectiveness of oxitocin to produce delivery without changing the myometrial oxytocin receptor Am. J. Obstet. Gynecol. 165, 1760–1770PubMedGoogle Scholar
  23. 23.
    Hill, N.C. et al. 1991 Transplacental passage of mifepristone and its influence on maternal and fetal steroid cencentrations in second trimester of pregnancy Hum. Reprod. 6, 458–462PubMedGoogle Scholar
  24. 24.
    Lim, B.H. et al. 1990 Normal development after exposure to mifepristone in early pregnancy Lancet 336, 257–258CrossRefPubMedGoogle Scholar
  25. 25.
    Pons, J.C., Papiernik, E. Mifepristone teratogenicity Lancet 338, 1332–1333Google Scholar
  26. 26.
    Wolf, J.P. et al. 1989 Noncopetitive antiestrogenic effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrated monkeys Fertil. Steril. 52, 1055–1060PubMedGoogle Scholar
  27. 27.
    Neulen, J. et al. 1990 RU 486 (Mifepristone): induction of dose dependent elevation of estradiol receptor in endometrium from ovariectomized monkeys JCEM 71, 1074–1075PubMedGoogle Scholar
  28. 28.
    Murphy,A.A. 1992 Progesterone antagonists in the treatment of endoemetriosis and leiomyomata uteri Abstract Terra Symposia III, Mohonk, NYGoogle Scholar
  29. 29.
    Kettel, L.M. et al. 1991 Endocrine response to long term administration of the antiprogesterone RU 486 in patients with pelvic endoemtriosis Fertil. Steril 56, 402–407PubMedGoogle Scholar
  30. 30.
    Schneider, M.R. et al 1992 The tumor-inhibiting potential of the progesterone anagonist onapristone in the mammary carcioma T61 in nude mice J. Cancer Res. Clin. Oncol. 118, 187–189CrossRefPubMedGoogle Scholar
  31. 31.
    Klijn, J.G. et al. 1989 Antiprogestins, anew form of ondocrine therapy for human breast cancer Cancer Res. 49, 2851–2856PubMedGoogle Scholar
  32. 32.
    Poulin, R. et al. 1989 Androgen and glucocortocoid receptor-mediated inhibition of cell proliferation by mydroxyprogesterone acetate in ZR-75-1 human breast cancer cells Breast cancer Res. Treat. 13, 161–172PubMedGoogle Scholar
  33. 33.
    Grunberg, et al 1991 Treatment of unrecestable menigiomas with the antiprogesterone agent mifepristone J. Nuerosurg. 74, 861–866Google Scholar
  34. 34.
    Bertagna, X. 1989 L'action antiglucocortocoide du RU 486. Ann. Endocrinol. (Paris) 50, 208–217Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Joseph Neulen
    • 1
  1. 1.Universitäts-FrauenklinikFreiburg im Breisgau

Personalised recommendations